Registry of Pancreatic Disease (PAD-R)
Registry of Subjects Affected by Pancreatic Disease and Evaluated at the Pancreas Institute of Verona
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Verona, Italy, 37124
- Recruiting
- AOUI Verona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- any type of pancreatic disease: inflammatory and neoplastic (including solid and cystic lesions)
Exclusion Criteria:
- physically or mentally inability to provide consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patient with pancreatic disease
Patients diagnosed with pancreatic disease evaluated at this institution.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 1 year
|
Survival from Diagnosis to time of death
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative morbidity
Time Frame: 90 days
|
Occurrence of Pancreatic Fistula, Biliary fistula, Enteric fistula, Delayed Gastric Emptying, Hemorrhage or Sepsis.
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Claudio Bassi, Prof, AOUI Verona
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PAD-R 1101CESC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasms
-
NCT07621718RecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | Pancreatic Ductal Adenocarcinoma (PDAC) | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic
-
NCT07573215AvailablePancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic | Metastatic Pancreas Adenocarcinoma
-
NCT06388967RecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II
-
NCT07491445RecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | Pancreatic Ductal Adenocarcinoma (PDAC) | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic
-
NCT07252232RecruitingPancreatic Cancer | Resected Pancreatic Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
-
NCT06673017RecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma
-
NCT02414100WithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT07549958RecruitingPancreatic Cancer | Pancreatic Cancer Metastatic
-
NCT07619521Not yet recruitingStage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma
-
NCT07591571Recruiting